Repligen Corp (RGEN) Shares Fall 7.7% -- What GF Score of 85 Tells Investors
On October 06, 2026, Repligen Corp (RGEN) shares experienced a notable decline of 7.7%, bringing the current price to $174.86. This movement comes amid a 52-wee
RGEN - Repligen Corporation
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$162.43
DETAILS
HIGH:
$225.00
LOW:
$142.00
MEDIAN:
$160.00
CONSENSUS:
$162.43
DOWNSIDE:
7.11%
Stock News
Repligen Completes Acquisition of BioLife Solutions
WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN, “Repligen”, or the “Company”), a life sciences company focused on bioprocessing technology leadership, today announced it has completed the previously announced acquisition of BioLife Solutions, Inc. (NASDAQ: BLFS, “BioLife”), a leading developer and supplier of cell processing tools and services for the cell and gene therapy market. “We are excited to welcome BioLife team members to Repligen,” said Olivier Loeillot, President and Chief Executive Officer of Repligen. “BioLife's highly-differentiated portfolio of products expands our presence in the rapidly growing cell therapy market, adding a deeply embedded, high-margin consumables business with attractive recurring revenue. Together, we are better positioned to support customers across critical stages of the cell therapy workflow and help advance the development and commercialization of next-generation therapies. Over the past several months, our teams have worked closely together to develop a thoughtful integration plan, and we are even more excited about the strategic rationale of bringing our organizations together and the value we will create for patients, customers, and shareholders.” BioLife's products are deeply embedded in the cell therapy workflow and highly complementary to Repligen's existing offering in this market. BioLife's differentiated biopreservation media portfolio, led by CryoStor®, supports 18 commercially approved therapies and the majority of U.S. commercially sponsored cell-based therapy trials. As a combined commercial team, BioLife will benefit from Repligen's broader global reach, including Asia Pacific, while Repligen will benefit from BioLife's trusted customer relationships. In connection with the transaction, BioLife stockholders received $11.25 per share in cash and 0.1442 shares of Repligen common stock, with cash in lieu of any fractional shares of Repligen common stock. Repligen intends to provide additional detail regarding the transaction's expected impact on Repligen's 2026 financial outlook in the upcoming third quarter 2026 earnings call. Advisors Perella Weinberg Partners LP and Goldman Sachs & Co. LLC served as financial advisors and Goodwin Procter LLP served as legal counsel to Repligen. Centerview Partners, LLC served as financial advisor and K&L Gates LLP served as legal counsel to BioLife. About Repligen Corporation Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve, primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, Germany, Ireland, the Netherlands and Sweden. For more information about the company see our website at www.repligen.com, and follow us on LinkedIn . Forward-Looking Statements This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements regarding the expected benefits of the transaction and Repligen's ability to recognize such benefits; the anticipated financial impact of the transaction on Repligen; expectations for Repligen's performance following the transaction; and beliefs and expectations about the cell therapy industry, including its growth, and BioLife's position as a highly-differentiated cell processing tool leader. Words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and variations of such words and similar expressions are intended to identify such forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law. Repligen Contact: Jacob JohnsonVP, Investor [email protected]
Repligen Corp (RGEN) Stock Up 4.3% but GF Value Says Overvalued -- GF Score: 85/100
On October 05, 2026, Repligen Corp (RGEN) shares rose 4.3%, bringing the current price to $189.50. The stock has experienced a 52-week range from a low of $100.
BioLife Solutions Shareholders Approve Repligen Merger Agreement
BioLife Solutions NASDAQ: BLFS stockholders approved the company's merger agreement with Repligen Corporation at a special meeting held virtually on Oct. 5, 2026, clearing a key shareholder-vote requirement for the proposed transaction.
Repligen (NASDAQ:RGEN) Hits New 52-Week High – Still a Buy?
Repligen Corporation (NASDAQ: RGEN - Get Free Report) reached a new 52-week high on Wednesday. The stock traded as high as $188.95 and last traded at $186.9330, with a volume of 25119 shares traded. The stock had previously closed at $186.75. Wall Street Analysts Forecast Growth A number of brokerages have issued reports on RGEN. HSBC
Tidal Investments LLC Raises Holdings in Repligen Corporation $RGEN
Tidal Investments LLC increased its stake in shares of Repligen Corporation (NASDAQ: RGEN) by 75.2% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,863 shares of the biotechnology company's stock after acquiring an additional 3,803 shares during
BioLife Solutions Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioLife Solutions, Inc. - BLFS
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of BioLife Solutions, Inc. (NasdaqCM: BLFS) to Repligen Corporation (NasdaqGS: RGEN). Under the terms of the proposed transaction, shareholders of BioLife will receive $11.25 in cash and 0.1442 shares of Repligen common stock for each share of BioLife that they own. KSF is seeking to determine whether t.
Repligen Corporation (RGEN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Repligen Corporation (RGEN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Why Is Repligen (RGEN) Up 27.7% Since Last Earnings Report?
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen
Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.
American Capital Management Inc. Makes New $49.26 Million Investment in Repligen Corporation $RGEN
American Capital Management Inc. acquired a new position in shares of Repligen Corporation (NASDAQ: RGEN) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 361,055 shares of the biotechnology company's stock, valued at approximately $49,262,000. Repligen comprises
5 Biotech Stocks Worth Adding to Your Portfolio Now
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, RGEN, IOVA, ARQT and PGEN in this volatile sector.
Repligen Corporation to Present at Wells Fargo 21st Annual Healthcare Conference
WALTHAM, Mass., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the Wells Fargo 21st Annual Healthcare Conference in Boston, MA. Olivier Loeillot, President and Chief Executive Officer and Jason Garland, Chief Financial Officer, will participate in an analyst-led discussion on September 9th at 1:30 p.m. ET.
25,992 Shares in Repligen Corporation $RGEN Acquired by Bank of Nova Scotia
Bank of Nova Scotia acquired a new stake in Repligen Corporation (NASDAQ: RGEN) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 25,992 shares of the biotechnology company's stock, valued at approximately $3,547,000. Several other institutional investors have also modified their holdings
Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here's Who's Best Positioned.
On August 19, 2026, Merck (NYSE:MRK | MRK Price Prediction) and Moderna (NASDAQ:MRNA) announced positive topline Phase 3 results from INTerpath-001 for intismeran autogene, an individualized neoantigen therapy paired with Keytruda in resected melanoma.
B. Metzler seel. Sohn & Co. AG Takes $3.60 Million Position in Repligen Corporation $RGEN
B. Metzler seel. Sohn and Co. AG acquired a new position in shares of Repligen Corporation (NASDAQ: RGEN) in the second quarter, according to its most recent disclosure with the SEC. The firm acquired 26,361 shares of the biotechnology company's stock, valued at approximately $3,597,000. Several other institutional investors and hedge funds also
Repligen Corporation $RGEN Shares Acquired by Avidity Partners Management LP
Avidity Partners Management LP increased its position in shares of Repligen Corporation (NASDAQ: RGEN) by 54.7% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 77,800 shares of the biotechnology company's stock after acquiring an additional 27,500
Wall Street Analysts Believe Repligen (RGEN) Could Rally 25.72%: Here's is How to Trade
The consensus price target hints at a 25.7% upside potential for Repligen (RGEN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Repligen Beats Q2 Earnings Estimates, Raises 2026 View, Stock Up
RGEN tops Q2 earnings and revenue estimates, lifts its 2026 revenue and EPS outlook, and sees shares jump after stronger-than-expected results.
Repligen Corporation (RGEN) Q2 2026 Earnings Call Transcript
Repligen Corporation (RGEN) Q2 2026 Earnings Call Transcript
Price Targets
Repligen assumed with a Buy at UBS
$225.00
(was $168.53)
UBS
Repligen price target raised to $160 from $150 at Evercore ISI
$160.00
(was $139.37)
Evercore ISI
Repligen resumed with an Outperform at RBC Capital
$160.00
(was $103.38)
Dan Leonard
·
RBC Capital
Repligen price target lowered to $142 from $152 at Jefferies
$142.00
(was $125.61)
Matthew Stanton
·
Jefferies
Repligen price target lowered to $145 from $165 at Canaccord
$145.00
(was $132.19)
Canaccord Genuity
Repligen initiated with a Buy at Rothschild & Co Redburn
$160.00
(was $127.09)
Redburn Partners
Repligen price target lowered to $145 from $175 at Barclays
$145.00
(was $122.59)
Luke Sergott
·
Barclays
Repligen price target raised to $200 from $190 at UBS
$200.00
(was $161.69)
Dan Leonard
·
UBS
Repligen price target raised to $190 from $175 at Wells Fargo
$190.00
(was $157.33)
Wells Fargo
Repligen price target raised to $200 from $175 at Barclays
$200.00
(was $157.33)
Barclays
Repligen price target raised to $165 from $150 at Canaccord
$165.00
(was $151.57)
Canaccord Genuity
Repligen price target raised to $175 from $160 at Barclays
$175.00
(was $151.57)
Barclays
Repligen (RGEN) PT Raised to $160 at Jefferies
$160.00
(was $154.24)
Matthew Stanton
·
Jefferies
Repligen price target raised to $160 from $150 at Barclays
$160.00
(was $145.81)
Luke Sergott
·
Barclays
Repligen initiated with a Buy at HSBC
$150.00
(was $133.67)
HSBC
Repligen price target raised to $205 from $204 at RBC Capital
$205.00
(was $120.69)
RBC Capital
KeyBanc Reiterates Overweight Rating on Repligen (RGEN)
$220.00
(was $148.59)
Paul Knight
·
KeyBanc
These Analysts Revise Their Forecasts On Repligen Following Q2 Results
$200.00
(was $167.35)
Rachel Vatnsdal
·
J.P. Morgan
These Analysts Revise Their Forecasts On Repligen Following Q2 Results
$185.00
(was $167.35)
Elizabeth Garcia
·
UBS
Deutsche Bank Upgrades Repligen (RGEN) to Buy
$155.00
(was $127.00)
Justin Bowers
·
Deutsche Bank